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Abstract
Background: Human B lymphocytes can produce leukotriene B4 but the biological function of the
5-lipoxygenase (5-LO) pathway in B cells is unclear. In order to better understand and define the
role of 5-LO in B cells, we investigated the expression of 5-LO mRNA and protein in subsets of B
cells from human tonsils and different types of B cell lymphoma.
Results: Based on RT-PCR and western blot/immunohistochemical staining, with a polyclonal
antibody raised against 5-LO, high expression of 5-LO was found in mantle zone B cells from
tonsils. By contrast, only a weak expression of 5-LO was detected in germinal centre cells and no
expression in plasma cells from tonsils. This pattern of 5-LO expression was preserved in malignant
lymphoma with high expression in mantle B cell lymphoma (MCL) and weak or no expression in
follicular lymphoma. Primary leukemized MCL, so called B-prolymphocytic leukaemia cells, and
MCL cell lines also expressed 5-LO and readily produced LTB4 after activation.
Conclusion: The present report demonstrates the expression of 5-LO mainly in normal and
malignant mantle zone B cells while the expression is low or absent in germinal centre B cells and
plasma cells, indicating a role of the 5-LO pathway in B cells before the cells finally differentiate to
plasma cells.
Background
Arachidonic acid can be converted to leukotrienes which
mediate inflammatory and immunological reactions [1].
The key enzyme in leukotriene biosynthesis is 5-lipoxyge-
nase (5-LO), which upon activation and interaction with
5-LO activating protein (FLAP) converts arachidonic acid,
via a two step process, to leukotriene (LT) A4. This com-
pound can easily be transformed into LTB4, through the
action of LTA4 hydrolase, or into LTC4, catalyzed by LTC4
synthase [1]. Leukotriene C4 can be further converted to
Published: 9 January 2009
BMC Immunology 2009, 10:2 doi:10.1186/1471-2172-10-2
Received: 17 September 2008
Accepted: 9 January 2009
This article is available from: http://www.biomedcentral.com/1471-2172/10/2
© 2009 Mahshid et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Immunology 2009, 10:2 http://www.biomedcentral.com/1471-2172/10/2
Page 2 of 12
(page number not for citation purposes)
LTD4 and LTE4. The biological effects of leukotrienes are
dependent on receptor interaction [1-5]. Leukotriene B4 is
a potent chemotactic mediator for granulocytes and T
lymphocytes [6-9]. Several reports have demonstrated a
function of LTB4 in the immune system as a stimulator of
monocytes, T lymphocytes and B lymphocytes [10-12].
Biosynthesis of leukotrienes is restricted to a few cell types
in the human body. Myeloid cells are the main source of
leukotriene formation but B lymphocytes have also the
capacity to produce LTB4. The activation of leukotriene
synthesis in B cells is quite different in comparison to
myeloid cells. Neutrophils and monocytes readily pro-
duce leukotrienes upon stimulation with calcium iono-
phore A23187. B cells, however, do not produce LTB4 after
challenge with calcium ionophore only but the cells can
produce similar amounts of LTB4 as myeloid cells after
changing the cellular oxidative status [13-15]. The 5-LO
activity in B cells appears to be latent and the mechanism
of activation of the enzyme under physiological condi-
tions is not yet known. Endogenously produced LTB4,
however, plays a pivotal role in CD40-dependent activa-
tion of chronic B lymphocytic leukaemia cells (B-CLL)
[16].
In resting neutrophils, 5-LO is localized in the cytoplasm
but upon cell activation the enzyme translocates to the
nucleus and nuclear membranes [17,18]. It has been pro-
posed that this translocation allows for 5-LO to interact
with FLAP on the nuclear membrane, thus enabling leu-
kotriene synthesis [1]. The localization of 5-LO seems,
however, to differ between different types of myeloid cells
[17-19]. Phosphorylation of 5-LO appears to influence
the nuclear import of 5-LO [20]. In B cell lines and iso-
lated B cells in vitro, both cytoplasmic and nuclear locali-
sation of 5-LO have been reported [14,21].
Mantle cell lymphoma (MCL) constitutes 5% of non-
Hodgkin lymphomas. Most MCL carry the
t(11;14)(q13;q32) translocation by which cyclin D1
becomes overexpressed [22,23]. Most MCL have unmu-
tated immunoglobulin genes [24] and the current
hypothesis is that the tumour cells are derived from the
mantle or marginal zone of the B cell follicles. Microarray
data of MCL have revealed high expression of 5-LO in
these cells in comparison to control lymphoid tissue [25].
The enzyme 5-LO has been reported to be expressed in
precursor B cells, B cell populations from the peripheral
blood, tonsils and various types of malignant B cells
[13,14,26]. However, it is not known which particular
subsets of B lymphocytes from the tonsils which can
express 5-LO and produce LTB4. Therefore, in order to
define the function of the leukotriene pathway in B cells,
we investigated the cellular expression of 5-LO in different
tonsillary subsets of B lymphocytes and the corresponding
type of malignant B cell lymphoma.
Results
PCR analysis of genes involved in the biosynthesis of 
leukotrienes in subsets of B cells
RT-PCR was performed on isolated total RNA from sub-
sets of tonsillary B cells to elucidate the gene expression of
enzymes involved in the leukotriene cascade. These anal-
yses demonstrated that 5-LO, FLAP and LTA4 hydrolase
were expressed in various degrees in tonsillary B cells
(CD19+), memory B cells (CD19+, CD38+, IgD-), mantle
zone B cells (CD19+, CD38+, IgD+) and germinal centre
(GC) B cells (CD19+, CD38++, IgD-). Highest relative
expression of these three genes was found in mantle zone
B cells and lowest expression in GC B cells (Figure 1).
These results indicate differential expression of these
enzymes in subpopulations of B cells. No investigated
subpopulation of B cells expressed LTC4 synthase.
Western blot analysis of 5-LO expression in subsets of B 
cells
Subpopulations of B cells from tonsils were separated by
flow cytometry and analyzed by western blot in order to
further characterize the expression of 5-LO. Whole cell
lysates of purified cells were submitted to SDS/PAGE fol-
lowed by western blotting using a polyclonal anti-human
5-LO antibody. A single immunoreactive band at the
expected size was observed in the sample consisting of
total B cells (CD19+) from tonsils, mantle zone B cells
(CD19+, CD38+, IgD+) and in memory B cells (CD19+,
CD38+, IgD-) and a weak band was detected in GC B cells
(CD19+, CD38++, IgD-) (Figure 2). In contrast, no band
was detected in samples from plasma cells (CD19+,
CD38+++, IgD-). There was a more marked difference in
the expression of the 5-LO protein than in the 5-LO
mRNA levels in the various subtypes of B cells (Figures 1
and 2).
Immunofluorescence analysis of 5-LO expression in 
subsets of tonsillar B lymphocytes
To identify the expression of 5-LO protein in subpopula-
tions of tissue tonsillar B cells, a panel of antibodies were
used to identify mantle zone B cells (IgD+), germinal cen-
tre B cells (CD38++) and plasma cells (CD38+++  or
CD138+). Figure 3A shows high expression of 5-LO in
mantle zone B cells (IgD+). In contrast, a very weak expres-
sion of 5-LO was observed in GC cells (CD38++) (Figure
3B). Figure 3C demonstrates no expression of 5-LO in
plasma cells (CD38+++) within the GC. Furthermore, no
expression of 5-LO was observed in plasma cells
(CD138+) outside the GC (Figure 3D). These results con-
cur with the western blot analysis of 5-LO in different sub-
sets of B cells (Figure 2).BMC Immunology 2009, 10:2 http://www.biomedcentral.com/1471-2172/10/2
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Immunohistochemical analysis of 5-LO expression in 
mantle cell lymphoma and follicular lymphoma
In order to further characterize the expression of 5-LO in
subsets of B cells, we investigated the expression of 5-LO
in malignant cells derived from the mantle zone and the
germinal centre i.e. mantle B cell lymphoma and follicular
lymphoma. For comparison, lymph node biopsies were
obtained from patients with reactive lymph nodes. In
agreement with the data shown in figure 3, the expression
of 5-LO in a reactive lymph node was mainly found in B
cells from the mantle zone rather than from the germinal
centre (Figure 4A). Interestingly, virtually all B cells
expressed 5-LO in a biopsy obtained from a patient with
MCL (Figure 4B). In contrast, corresponding analyses of
biopsies from patients with follicular lymphoma, demon-
strated that very few cells expressed 5-LO. These cells are
most likely dendritic cells or tangible body macrophages
as described earlier [27] (Figure 4C). No staining was
observed with control antibody (Figure 4D). Similar
results were obtained with another 5-LO antiserum (data
not shown). Taken together, all investigated biopsies from
patients with mantle zone B cell lymphoma clearly
expressed 5-LO, whereas, little or none staining was
observed in biopsies from patients with follicular lym-
phoma (Table 1).
As a comparison, tonsillar polymorphonuclear granulo-
cytes expressed 5-LO in the nucleus (Figure 4E), in con-
trast to tonsillar CD3 positive T lymphocytes which did
not express 5-LO (Figures 4F and 4G). The IHC in figure
4G was stained with human anti-CD3 antibody.
Biosynthesis of LTB4 in mantle B cell lymphoma
Since it was difficult to isolate large numbers of tonsillary
non-malignant mantle zone B cells for chemical analysis,
we used MCL cells to study the biosynthesis of LTB4 in
Semiquantitative RT-PCR analysis of enzymes in the leukotriene pathway in subpopulations of B cells from tonsils Figure 1
Semiquantitative RT-PCR analysis of enzymes in the leukotriene pathway in subpopulations of B cells from 
tonsils. Semiquantitative RT-PCR analysis was performed on purified non-fractioned B cells (tonsillary), memory B cells, man-
tle zone B cells and germinal centre B cells. The figure depicts the expression of 5-LO, FLAP, leukotriene A4 hydrolase 
(LTA4H) and leukotriene C4 synthase (LTC4S). Highest relative expression of 5-LO, FLAP and LTA4H was found in mantle 
zone B cells. The gene expression of LTC4S was absent in all the three investigated B cell subpopulations. The values are pre-
sented as "Transcripts/GAPDH 103 transcripts". Values represent experiments performed from two independent tonsils with a 
minimum of duplicate RT-PCR experiment per gene (mean ± SD).BMC Immunology 2009, 10:2 http://www.biomedcentral.com/1471-2172/10/2
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mantle zone B cells. For this purpose, we used both differ-
ent MCL cell lines and primary MCL cells isolated from
the peripheral blood of patients with leukemized MCL, so
called prolymphocytic leukemia (B-PLL) with t(11;14). B-
PLL is in fact a heterogenous disease and those cases that
are positive for cyclin D1 and carry the t(11:14) transloca-
tion are in the current WHO classification of malignant
lymphomas [22] considered to be leukemic forms of MCL
[28,29]. All three investigated MCL cell lines (Granta 519,
JEKO-1 and Rec1) expressed 5-LO protein (Figure 5). Fig-
ure 6 depicts the capacity of B-PLL cells and MCL cell lines
to produce leukotrienes. The challenge of B-PLL cells with
ionophore A23187 plus arachidonic acid and the thiol-
active compound Diamide led to the formation of similar
amounts of LTB4 as produced by human neutrophils (Fig-
ure 6A) [30]. This cocktail of compounds is known to
induce LTB4 production in other types of B lymphocytes
[14]. Sonicated cells also readily produced LTB4 (Figure
6A). Upon calcium ionophore activation only, isolated B-
PLL produced low amounts of LTB4 (about 1 pmol/106
cells), showing that there were minimal amounts of mye-
loid cells contaminating these preparations of B-PLL cells.
Figure 6B shows that intact or sonicated Granta 519,
JEKO-1 and Rec1 cells also produced significant amounts
of LTB4 as B-PLL cells. The capacity of the different cell
lines to produce LTB4 correlated relatively well with the
degree of expression of 5-LO protein (Figures 5 and 6B).
In essence, these results demonstrate that both B-PLL cells
and MCL cell lines have the capacity to produce LTB4 and
that the cells contained substantial amounts of 5-LO,
which could be activated under certain conditions.
Discussion
The activation mechanisms and biological functions of 5-
LO in human B lymphocytes are unclear although the
overall capacity of B cells to produce LTB4 is similar to
myeloid cells [30]. We purified various subpopulations of
tonsillary B cells and investigated the expression of
enzymes involved in the leukotriene pathway. RT-PCR
and western blot analysis of B cells from tonsils separated
by flow cytometry showed high expression of 5-LO, in
particular mantle zone B cells but also memory B cells
(Figures 1 and 2), while germinal centre cells and plasma
cells showed low or no expression of 5-LO, respectively.
This analysis also demonstrated that FLAP and LTA4
hydrolase were expressed in these various B cell popula-
tions (Figure 1). In order to further investigate the expres-
sion of the 5-LO protein, immunofluorescence analyses of
tonsillary tissue B cells were performed. A distinct expres-
sion of 5-LO was seen in IgD+ B cells in the mantle zone,
while only a weak expression was found in germinal cen-
tre B cells and virtually no expression in plasma cells (Fig-
ure 3).
To verify if the expression of 5-LO was preserved in malig-
nant B cells we investigated MCL and FL. Mantle cell lym-
phomas have a lower somatic mutation rate in
immunoglobulin genes than follicular lymphomas and
approximately 60–75% of mantle cell lymphomas have
immunoglobulin genes in germ-line configuration. There-
fore, it has been hypothesized that mantle cell lympho-
mas are derived from naïve cells, similar to normal mantle
zone B cells [31]. Immunohistochemical analysis of biop-
sies from MCL patients showed high expression of 5-LO
in virtually all cells (Figure 4B). Follicular lymphomas, on
the other hand, have a high rate of somatic mutations in
immunoglobulin genes and clearly originate from germi-
nal centre B cells [31]. There were no or low expression of
5-LO in follicular lymphoma cells and this concur with
the results of normal germinal centre B cells (Figures 2, 3,
4A, 4C and Table 1).
Western blot analysis of 5-LO expression in B cells from tonsils Figure 2
Western blot analysis of 5-LO expression in B cells from tonsils. Western blot was performed on different subpopula-
tion of B cells isolated from tonsils (5 μg total protein/sample). Lane 1 – total B cells from tonsils, lane 2-mantle zone B cells, 
lane 3 – germinal centre B cells, lane 4 – plasma B cells, lane 5 – memory B cells and lane 6 – HL60 cells differentiated with 
DMSO (positive control). 5-LO protein was detected in all subpopulations except for plasma cells, with highest relative band 
intensity in mantle zone and memory B cells. The figure represents one typical experiment out of three independent experi-
ments.BMC Immunology 2009, 10:2 http://www.biomedcentral.com/1471-2172/10/2
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Immunofluorescence analysis of 5-LO expression in subsets of tonsillar B lymphocytes Figure 3
Immunofluorescence analysis of 5-LO expression in subsets of tonsillar B lymphocytes. Tonsils were prepared for 
immunofluorescence analyses and stained with anti-IgD, anti-CD38, anti-CD138 and DAPI. A) B cells within the mantle zone 
were stained with anti-IgD (green, A1); anti-5-LO (red, A2) and DAPI (blue, A3). The combined picture (A4 (A1+A2+A3)) 
depicts high expression of 5-LO in IgD+ cells. B) Germinal centre B cells were stained with anti-CD38 (green, B1); anti-5-LO 
(red, B2) and DAPI (blue, B3). The combined picture (B4 (B1+B2+B3)) shows very weak expression of 5-LO in CD38++ cells. 
C) Plasma cells within the germinal centre were stained with anti-CD38 (green, C1); anti-5-LO (red, C2) and DAPI (blue, C3). 
The combined picture (C4 (C1+C2+C3)) demonstrates no expression of 5-LO in CD38+++ cells. D) Plasma cells outside the 
germinal centre were stained with anti-CD138 (green, D1); anti-5-LO (red, D2) and DAPI (blue, D3). The combined picture 
(D4 (D1+D2+D3)) depicts no expression of 5-LO in CD138+ cells. The figure represents one out of four examined tonsils.BMC Immunology 2009, 10:2 http://www.biomedcentral.com/1471-2172/10/2
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Immunohistochemical staining of 5-LO in MCL and FL biopsies Figure 4
Immunohistochemical staining of 5-LO in MCL and FL biopsies. B cells in the mantle zone from reactive tonsils and 
mantle cell lymphoma express 5-LO. A) reactive lymph node, right part displays the mantle zone and the left part the germinal 
centre; B) mantle cell lymphoma; C) follicular lymphoma; D) negative control without primary antibody; E) nuclear staining of 
5-LO in neutrophils from a normal tonsil; F) T-cells (CD3+) around the mantle zone are 5-LO negative, (figure G is stained 
with human anti-CD3 antibody). Pictures were taken with a 40×/0.85 numerical aperture (NA) and a 100×/1.30 NA objective 
lens. GC – germinal centre; MZ – mantle zone. The figure is a representative picture of the investigated samples listed in table 
1.BMC Immunology 2009, 10:2 http://www.biomedcentral.com/1471-2172/10/2
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There are conflicting data about the expression of 5-LO in
T cells. We have previously reported that T cells express
FLAP but not 5-LO [13], whereas, one other report indi-
cates the formation of LTB4 by human T cells [32]. We
found no evidence for the expression of 5-LO protein in
CD3 positive tonsillar T cells (Figure 4F).
Since the numbers of tonsillary mantle zone B cells that
can be obtained by flow cytometry cell sorting is limited,
we investigated the capacity to produce LTB4 in primary B-
PLL cells and cell lines derived from patients with MCL.
Three different MCL cell lines were used in this study and
all were found to express 5-LO and to have the capacity to
produce LTB4 (Figures 5 and 6). Also, primary B-PLL cells
Table 1: Expression of 5-lipoxygenase in reactive lymphoid tissue, mantle cell lymphoma and follicular lymphoma
Patient number Age Sex Tumor Subtype 5-LO Expression
1 56 F Lymph node N.A. moderate
2 19 F Lymph node N.A. moderate
3 43 F Tonsil N.A. moderate
4 90 M MCL classic moderate
5 83 M MCL classic strong
6 56 M MCL classic strong
7 82 F MCL classic moderate
8 81 F MCL classic weak
9 77 M MCL classic strong
10 81 M MCL classic strong
11 49 M MCL classic strong
12 63 F MCL blastoid weak
13 68 M MCL blastoid moderate
14 37 M FL FL1 weak
15 70 F FL FL1 weak
16 34 F FL FL1 negative
17 73 M FL FL2 negative
18 40 F FL FL2 negative
19 73 F FL FL2 negative
20 58 M FL FL2 negative
21 61 M FL FL3a negative
22 66 M FL FL3a negative
23 49 F FL FL3a negative
5-LO protein expression was evaluated by immunohistochemistry. Samples of reactive lymphoid tissue (lymph nodes, (n = 2) and tonsil, (n = 1)), 
mantle cell lymphoma (MCL), classic and blastoid variants (n = 10) and follicular lymphoma (FL), malignancy grades 1-3a (n = 10) were collected in 
a tissue microarray and simultaneously stained. The age and the sex of the patients are indicated. Expression of 5-LO in lymphoma cells was 
semiquantified in four levels; absence of staining in tumor cells (negative), weak staining (weak), moderate staining (moderate) and strong staining 
(strong) as compared to cells in reactive mantle zones that were moderately positive. N.A. = not applicable
Western blot analysis of 5-LO in three MCL cell lines Figure 5
Western blot analysis of 5-LO in three MCL cell lines. Western blot was performed on three different MCL cell lines 
(Granta 519, JEKO-1 and Rec1) with an anti-human 5-LO antibody. Lane 1 – PMNL (positive control), lane 2 – Granta 519, lane 
3 – JEKO-1 and lane 4 – Rec1. An aliquot (7 μg) of total protein was analysed for each sample. The figure represents one 
experiment out of three independent experiments.BMC Immunology 2009, 10:2 http://www.biomedcentral.com/1471-2172/10/2
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produced LTB4 in amounts similar to that of myeloid cells.
Primary MCL/B-PLL cells and MCL cell lines produced
LTB4 after being challenged with calcium ionophore plus
arachidonic acid and Diamide but not after stimulation
with calcium ionophore only, showing that the mecha-
nism of activation of the leukotriene pathway in MCL cells
is similar to other investigated B cells [16,26,33].
This study and earlier reports demonstrate that 5-LO is
expressed in peripheral B cells, IgD+ B cells in the mantle
zone, memory B cells and in various malignant B cells, e.g.
CD10+  acute pre-B-lymphocytic cells, chronic B-lym-
phocytic leukaemia, B-PLL and MCL [13,14,26]. Investi-
gated B lymphocytes that do not express 5-LO are
germinal centre derived B cells, plasma cells and CD10-
acute pre-B-lymphocytic cells. The question if and under
which conditions B lymphocytes can release LTB4 in vivo,
is still unclear. In fact, it is possible that the role of the 5-
LO pathway is quite different in B cells than in myeloid
cells, and that the pathway has only an endogenous func-
tion in B cells which do not release and export LTB4. Thus,
in B cells, 5-LO and LTB4 might only have a role at the
level of the nucleus. However, the physiological condi-
tions required for activation of the 5-LO pathway in B cells
and biosynthesis of LTB4 have not yet been uncovered. In
this regard, the cellular oxidative status of the cells seems
to be of importance [13-15]. Our finding that the enzyme
is highly expressed in mantle zone B cells and less
expressed in germinal centre B cells and not expressed in
plasma cells could indicate that the enzyme might be acti-
vated in the lymph node to attract activated T cells. It is
known that activated T cells express BLT1, the LTB4 recep-
tor, and that LTB4 is a potent chemotactic agent for T cells
[7-9]. Therefore, we will now study the effect of T- and B
lymphocyte interaction on the activity and expression of
5-LO.
Conclusion
In summary, the present study demonstrates high expres-
sion of 5-LO mantle zone B cells but not in germinal cen-
tre B cells or plasma cells indicating a role of the 5-LO
pathway in B cells before the cells differentiate to plasma
cells.
Methods
Reagents and cell lines
The calcium ionophore A23187 was purchased from Cal-
biochem-Behring (La Jolla, CA, USA). HPLC solvents were
Biosynthesis of LTB4 by B-PLL cells and MCL lines Figure 6
Biosynthesis of LTB4 by B-PLL cells and MCL lines. Intact cells (10 × 106) were pre-incubated for two min at 37°C, in 
the presence of Diamide (100 μM), prior to addition of A23187 (1 μM) plus arachidonic acid (AA) (40 μM) for five min. Soni-
cated cells (homogenate) were pre-incubated with ATP (1 mM) for two min at 37°C and then incubated with calcium chloride 
(2 mM) and arachidonic acid (40 μM) for five min. Panel A depicts the formation of LTB4 in B-PLL cells isolated from four differ-
ent donors (mean ± SD). Panel B depicts the formation of LTB4 in three different MCL lines i.e. Granta 519, JEKO-1 and Rec1 
(mean ± SD, from three independent experiments).BMC Immunology 2009, 10:2 http://www.biomedcentral.com/1471-2172/10/2
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obtained from Rathburn chemicals (Walkerburn, U.K.)
and the synthetic standards of LTB4 and prostaglandin
(PG) B1 were from Biomol (Plymouth, PA, USA). Azodi-
carboxylic acid bisdimethylamide (Diamide) was from
Sigma-Aldrich (Stockholm, Sweden) and arachidonic acid
(AA) from NU-CHEK PREP Inc. (MN, USA). The well-
characterized MCL cell lines Granta 519 and JEKO-1 were
purchased from Deutsche Sammlung von Microorganis-
men und Zellkulturen (DSMZ) (Braunschweig, Ger-
many). The MCL cell line Rec1 [34] was a generous gift
from Dr. Christian Bastard (Ronan, France). Cell lines
were maintained in RPMI 1640 medium (Invitrogen Life
Technologies, Stockholm, Sweden) supplemented with 2
mM L-glutamine and 10% fetal calf serum (FCS) and 50
μg/mL gentamicin (Invitrogen) under standard condi-
tions (humidified atmosphere, 95% air, 5% CO2, 37°C).
JEKO-1 was maintained as described above but with a
final concentration of 20% FCS.
Isolation of subpopulations of B cells
Tonsils were obtained from patients undergoing tonsillec-
tomies (HELIOS Klinikum, Erfurt, Germany). Isolated
cells from tonsils were incubated with CD19 micro beads
(Miltenyi, Germany) and loaded in a magnetic field on a
MACS separation column LS (Miltenyi). Cells were
washed three times with PBS/EDTA (2 mM)/FCS (5%),
subsequently the column was removed from the magnetic
field and CD19 positive cells were eluted with 4–6 mL
PBS/EDTA/FCS. Isolated cells were concentrated to 107
cells/50 μL and incubated with anti-CD38-PE (Pharmin-
gen, Germany) and anti-IgD-FITC (Pharmingen) for 20
min at 4°C. Cells were washed twice, set to 2 × 106 cell/
mL in PBS/EDTA/FCS and sorted with a FACSVantage SE
cell sorting instrument (Beckton Dickinson, Germany). B
cells were classified according to the scheme described by
Grammer et al. 1999 [35], mantle zone B cells (CD19+,
IgD+, CD38+), germinal centre B cells (CD19+, IgD-,
CD38++), memory B cells (CD19+, IgD-, CD38+) and
plasma cells (CD19+, IgD-, CD38+++). Only cell popula-
tions that were > 95% pure were used in further experi-
ments.
Isolation of total RNA and RT-PCR
Total RNA was separated according to the manufacturer's
protocol with an RNeasy mini kit (Qiagen, Germany).
Concentration and quality of RNA was determined with a
Bioanalyzer2100 (Agilent, Germany). The reversed tran-
scription reaction was performed on 1.8 μg of total RNA
in a RT-PCR mixture (1× RT buffer, 167 μM dNTP, 0.7 U/
μL RNasin, 0.1 μg/μL BSA, 0.35 U/μL AMV reverse tran-
scriptase (Roche, Germany)).
PCR
PCR was performed with 60 ng of cDNA for each reaction.
The PCR reaction mixture contained; PCR buffer, dNTP
mix (0.2 mM each), BSA (0.1 μg/μL), SybrGreen (1:50)
(Roche), MgCl2 (1.8 mM), Platinum Taq DNA polymer-
ase (1.5 U) (Invitrogen, Germany) and primer mix (0.2
μM each). Primers that were used are described in table 2.
Western blot
Tonsillary B cell samples were washed in PBS (2×) and re-
suspended to 4 × 104 cells/μL in 5× sample buffer (250
mM Tris/HCl pH 6.8, 30% Glycerol (v/v), 10% SDS (w/v),
5%  β-mercaptoethanol (v/v), 0.02% Bromphenolblue
(w/v), complete mini protease inhibitor (Roche)). The
suspension was heated to 95°C (5–10 min) and run on a
regular 10% SDS-PAGE with SDS running buffer (25 mM
Tris/HCl; 190 mM Glycine; 0.1% SDS (w/v)). HybondC
nitrocellulose membrane (GE Healthcare, Germany) and
semi-dry blotting apparatus (LMS labortechnik, Ger-
many) was used for western blot transfer. The detection
was performed with ECL kit (GE Healthcare, Germany).
Primary antibody used for the immunoblot detection was
anti-5-LO polyclonal rabbit antiserum [36] and secondary
antibody was an anti-rabbit-IgG coupled with HRP (GE
Healthcare, Germany).
MCL cell lines were washed in PBS (w/o calcium and mag-
nesium) and suspended in PBS (w/o calcium and magne-
sium) supplemented with complete mini protease
inhibitor (Roche, Sweden). Cells were sonicated on ice (3
× 5 seconds) (Sonics Vibra cell, 40% amplitude, CiAB,
Table 2: List of primers that were used in the RT-PCR experiment
Gene Annealing temp. Size of PCR Product sequence
5-LO 72°C 486 bp 5'ACCATTGAGCAGATCGTGGACACGC
3'GCAGTCCTGCTCTGTGTAGAATGGG
FLAP 71°C 352 bp 5'GGCCATCGTCACCCTCATCAGCG
3'GCCAGCAACGGACATGAGGAACAGG
LTA4H 72°C 464 bp 5'GCAGTCACGGGATGCATGCTTGCT
3'GCCTGGCTCTACTCTCCTGGACTG
LTC4S 68°C 252 bp 5'TGCCACCACACCGACGGTACCATG
3'CCCTTCATGAAAGAAGATGCCGGBMC Immunology 2009, 10:2 http://www.biomedcentral.com/1471-2172/10/2
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Sweden) and centrifuged (1 × 105 × g, 60 min, 4°C).
Supernatant was collected and protein concentration was
determined with Bradford. Protein (7 μg) was loaded and
separated on a 7% tris-acetate gel. PVDF membrane (GE
Healthcare, Sweden) and semi-dry blotting apparatus (GE
Healthcare, Sweden) was used in the western blot transfer.
Immunofluorescence analysis of tonsillary B cells
Confocal laser scan microscopy was performed with 7 μm
cryostat sections embedded in Tissue Tec (Sakura, Japan).
Specimens were placed on glass slides and fixed with ace-
tone for 15 min at 4°C. After rehydration in PBS supple-
mented with BSA (2%) for 30 min at 20°C, specimens
were incubated for 1 h at room temperature with rabbit
anti-5-LO antiserum and for double immunofluorescence
analyses with unlabeled primary antibodies against IgD
and CD38 (Pharmingen), CD19 (Coulter Immunotec) or
CD138 (Serotec). Nuclei were counterstained with DAPI.
Secondary antibodies (goat anti-mouse-IgG F(ab')2-Cy2
and donkey anti-rabbit-IgG F(ab')2-Cy3; Dianova) were
applied for 1 h at room temperature. Sheets were
mounted on coverslips with Permafluor (Beckman,
Munich, Germany) and viewed on a Zeiss Axiovert 200 M
microscope equipped with a confocal laser scanning head
(LSM510). Pictures were taken and analyzed using
LSM510 Image Examiner software (Zeiss, Jena, Germany).
Immunohistochemistry on Tissue Microarray (TMA)
Formalin-fixed, paraffin-embedded tumor (lymph nodes)
tissue samples and hyperplastic tonsils were obtained
from the Department of Pathology, Karolinska University
Hospital Huddinge. Before constructing a TMA block,
serial 5 μm sections were cut from each donor block. One
of these sections was stained with H&E for marking mor-
phologically representative areas of the tumor. One repre-
sentative area was targeted. Using Beecher Instruments
Tissue Arrayer (Silver Springs, MD, USA), tissue cylinders
with a diameter of 1.0 mm were punched from the tar-
geted area in each donor block and deposited into a recip-
ient TMA block. The cores of each TMA included duplicate
cores from all cases and two cores of normal human heart
muscles as a control for orientation of the sections.
Multiple serial 5 μm-thick TMA sections containing sam-
ples were cut de-paraffinized in xylene and hydrated in a
series of graded alcohols. Enzyme digested antigen
retrieval was carried out with Protease (Sigma P-5147,
Sweden) at 20°C for 10 min. Anti-5-LO antibody (LO-32,
Merck Frosst, Canada) was used at a dilution of 1:300 and
anti-CD3 antibody was used at a dilution of 1:100
(DAKO). All staining were semiautomatic and performed
on a TechMate 500 plus (DAKO, Glostrup, Denmark) by
using the Dako REAL™ Detection System, PeroxidaseDAB,
RabbitMouse kit as recommended by the manufacturer.
The results of the staining were evaluated by three persons
(XW, BC and BS). Images of immunohistologic staining
were acquired using an Olympus BX45 microscope
(Olympus, Stockholm, Sweden) and Sony digital camera
(DXC-S500, Sony, Stockholm, Sweden). Digitized images
were processed using Picsara 8.9 Rev 5 software (Bildana-
lyssytem AB, Stockholm, Sweden).
Incubation of B-PLL cells and MCL cell lines
Intact cells (10 × 106) were suspended in 1 mL phosphate
buffered saline (PBS) and pre-incubated for two min with
azodicarboxylic acid bisdimethylamide (Diamide) (100
μM) prior to stimulation with arachidonic acid (40 μM)
and calcium ionophore A23187 (1 μM). The cells were
stimulated for five min and the reaction was terminated
with 1 mL methanol. The A23187 incubation was per-
formed as described above but without any addition of
Diamide and arachidonic acid. Alternatively, cells (10 ×
106) were re-suspended in 1 mL calcium free PBS includ-
ing EDTA (2 mM) and sonicated for 3 × 5 seconds. The
cells were pre-incubated for two min at 37°C in the pres-
ence of ATP (1 mM) prior addition of calcium chloride (2
mM) and arachidonic acid (40 μM). The reaction was ter-
minated after five min of incubation with 1 mL methanol.
Analysis of leukotrienes
After addition of PBS (0.5 mL) and the internal standard
PGB1 (50 pmol), the samples were centrifuged (1250 × g,
5 min). The supernatants were subsequently subjected to
solid phase extraction on Oasis HLB Extraction Cartridges
(10 mg, Waters, Sweden). The methanol fractions were
analyzed on a Waters Alliance 2695 reverse phase HPLC
and detected with Waters PDA 996. Methanol:water:trif-
luoroacetic acid (70:30:0.007, v/v) was used as mobile
phase at a flow rate of 1.2 mL/min. Qualitative analysis
was performed by comparison of retention times of syn-
thetic standards and quantitative determinations were
performed by computerized integration of the area of
eluted peaks. Mean and standard deviation was calcu-
lated.
Ethical perspective
This study was approved by the local ethic committee of
Friedrich-Schiller-University of Jena, Germany, and Karo-
linska University Hospital, Stockholm, Sweden.
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